Based on the Co-Diagnostics Inc stock forecast from 1 analysts, the average analyst target price for Co-Diagnostics Inc is USD 1.25 over the next 12 months. Co-Diagnostics Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Co-Diagnostics Inc is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, Co-Diagnostics Inc’s stock price was USD 0.35. Co-Diagnostics Inc’s stock price has changed by +16.93% over the past week, -27.71% over the past month and -70.41% over the last year.
No recent analyst target price found for Co-Diagnostics Inc
No recent average analyst rating found for Co-Diagnostics Inc
Company Overview Co-Diagnostics Inc
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Read Less
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platfor...Read More
Frequently Asked Questions About Co-Diagnostics Inc (CODX) Stock
Based on ratings from 1 analysts Co-Diagnostics Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on CODX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for CODX is USD 1.25 over the next 12 months. The maximum analyst target price is USD 1.5 while the minimum anlayst target price is USD 1.
CODX stock's Price/Earning ratio is 5.90.
Our analysis grades CODX stock's Price / Earning ratio at D-. This means that CODX stock's Price/Earning ratio is above 39% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this CODX may be fairly valued for its sector
The last closing price of CODX's stock was USD 0.35.
The most recent market capitalization for CODX is USD 0.01B.
Based on targets from 1 analysts, the average taret price for CODX is projected at USD 1.25 over the next 12 months.
This means that CODX's stock price may go up by +257.04% over the next 12 months.
We can't find any ETFs which contains Co-Diagnostics Inc's stock.
As per our most recent records Co-Diagnostics Inc has 132 Employees.
Co-Diagnostics Inc's registered address is 2401 South Foothill Drive, Salt Lake City, UT, United States, 84109.
You can get more information about it from Co-Diagnostics Inc's website at https://co-dx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Co-Diagnostics Inc (CODX) Stock
Based on ratings from 1 analysts Co-Diagnostics Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on CODX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for CODX is USD 1.25 over the next 12 months. The maximum analyst target price is USD 1.5 while the minimum anlayst target price is USD 1.
CODX stock's Price/Earning ratio is 5.90.
Our analysis grades CODX stock's Price / Earning ratio at D-. This means that CODX stock's Price/Earning ratio is above 39% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this CODX may be fairly valued for its sector
The last closing price of CODX's stock was USD 0.35.
The most recent market capitalization for CODX is USD 0.01B.
Based on targets from 1 analysts, the average taret price for CODX is projected at USD 1.25 over the next 12 months.
This means that CODX's stock price may go up by +257.04% over the next 12 months.
We can't find any ETFs which contains Co-Diagnostics Inc's stock.
As per our most recent records Co-Diagnostics Inc has 132 Employees.
Co-Diagnostics Inc's registered address is 2401 South Foothill Drive, Salt Lake City, UT, United States, 84109.
You can get more information about it from Co-Diagnostics Inc's website at https://co-dx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CODX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
